Downregulation of Cystine
The amino acid transporter system x c -is a heterodimer consisting of the SLC7A11 light chain (xCT) and the SLC3A2 heavy chain (4F2hc, also known as CD98) [1] . The xCT component is unique to system x c -, while 4F2hc is present in many transport systems. System x c -is a cystine-glutamate exchanger associated with cellular response to stress and production of the antioxidant glutathione (GSH). GSH is a tripeptide thiol containing glutamate, cysteine and glycine and is important for the cellular defense against oxidative stress and is a free radical scavenger and detoxifying agent [2] . Glutamate and glycine are amino acids that are abundant intracellulary, whereas cysteine is the rate-limiting amino acid in syn-thesis of GSH, underscoring the requirement for the functional system x c -to facilitate the uptake of cystine which will reduce to cysteine intracellulary. Many other factors influence the GSH levels, including ␥ -glutamylcysteine synthetase ( ␥ -GCS) expression and activity, along with oxidative stress and antioxidants [3] .
GSH is required by cancer cells to combat the significantly increased reactive oxygen species (ROS) during their growth. In cancer cells, GSH regulates DNA synthesis, cell growth, radiation resistance and also multidrug resistance, making it a target for cancer therapy [4, 5] . Depletion of GSH leads to inhibition of drug efflux by multidrug resistance proteins (MRPs) resulting in the increased intracellular accumulation of drugs, and reduction of drug resistance [6] [7] [8] . Importantly, GSH is responsible for the detoxification of certain drugs [9] and GSH depletion has been linked to the therapeutic efficacy of some anticancer drugs [10, 11] .
Increased GSH synthesis requires enhanced cystine uptake [12] [13] [14] by cystine transporter system x c -which consists of xCT, a catalytic light chain. To determine chemical compounds that are susceptible to GSH mediated chemoresistance, Dai et al. applied chemoinformatics analysis with panel 3045 (NCI 3K) anticancer compounds on NCI-60 cells and found ϳ 15% of these compounds yielded negative correlation (resistance) with the xCT (SLC7A11) [15] . This result indicates that there are tumors in which the resistance is attributed to xCT overexpression, which provides the basis for the development of new anticancer drugs targeting xCT. Previously, Huang et al. demonstrated a correlation of SLC7A11 expression and geldanamycin resistance mediated by GSH [16] . Furthermore, the chemoinformatics analysis revealed that the SLC7A11-drug correlation was significantly greater than the other SLC7A sub family genes, ␥ -GCS, GSTP1 and other chemoresistance genes like ABCB1 (MDR1) and ABCC1 (MRP1) tested in NCI-60 cells, indicating that SLC7A11 plays an important role in chemomodulation [15] . Recently, xCT has been recognized as an important molecular target for the therapy of various diseases including cancer [5] .
Irinotecan is used as a chemotherapeutic agent in the treatment of various solid tumors including colorectal cancer and lung cancer [17, 18] . Irinotecan is a topoisomerase I (topo I) inhibitor that induces DNA double strand breaks and cell death. SN-38, the active metabolite of irinotecan, has been reported as the inducer of ROS in gastric cancer cells [19] . Based on this, one can reasonably expect that SN-38 may downregulate intracellular GSH levels. The anticancer drug topotecan belongs to the irinotecan family and exerts its cytotoxic effects through the increased production of ROS [20] . The ROS-generating compounds induce apoptotic pathways in MDA-MB-231 human breast carcinoma cells [21] and rat glioma cells [22] . Given the importance of system x c -in the synthesis of GSH and the key role of GSH in cancer cell growth, we investigated the role of irinotecan in the regulation of GSH in FaDu tumor xenografts and FaDu cells in vitro. FaDu, a human epithelial cell line from squamous cell carcinoma of the hypopharynx was isolated and established from a patient [23] . Additionally, we and others found that xCT of the cystine transporter system x c -played the key role in acquiring cysteine for the synthesis of GSH [24] [25] [26] . Collectively, our data indicate that the observed reduction of GSH and concomitant increase in ROS level as a consequence of downregulation of xCT by irinotecan represent a potential new mechanism in addition to the inhibition of topo I.
Materials and Methods

Mice
Female athymic nude mice ( Foxn1 nu ; Harlan Sprague-Dawley, Inc. Indianapolis, Ind., USA) that were 8-12 weeks old were maintained in the animal facility. All studies were performed in accordance with protocols approved by the institutional animal care and use committee at Roswell Park Cancer Institute.
Drugs
Irinotecan was purchased from Pfizer (formerly Pharmacia and Upjohn Co., Kalamazoo, Mich., USA) in 5-ml aliquots as 'ready to use' clinical formulations containing 100 mg drug (20 mg/ml). SN-38 was purchased from Pharmacia and dissolved in DMSO. The required final drug concentrations for in vitro experiments were obtained by diluting in growth medium. Monosodium glutamate (MSG) and sulfasalazine were obtained from Sigma-Aldrich (St. Louis, Mo., USA).
Determination of External Cystine Requirement for the Growth of Cancer Cells
FaDu and other cancer cells (A253, A549, PC3; purchased from ATCC) free of Mycoplasma tested periodically using Mycoplasma T.C. rapid detection system (Gen-Probe, Inc., San Diego, Calif., USA), were used to determine the cystine requirement for growth. Special RPMI-1640 medium (Cat No. 17-104-Cl; Mediatech, Herndon, Va., USA) without L -cystine, L -glutamine and Lmethionine was used. To make the complete medium, 2.05 m M glutamine (300 mg/l) and 100 M methionine (15 mg/l), the concentrations present in the regular RPMI-1640, were added. In contrast to this, 84 M of cystine was added at its physiological concentration [27] , which is approximately one third of the regular RPMI-1640 medium. Approximately 300-400 cells in each well of a 96-well plate were grown overnight in regular RPMI-1640 medium with 10% fetal bovine serum (FBS). Non-dialyzed FBS was used in all the media and experimental conditions. Cells were washed three times with sterile PBS (pH 7.2, 37 ° C) and special RPMI-1640 medium with and without cystine and/or methionine was added and cells were allowed to grow for 5 days with fresh media replacement on the third day. Control cells were maintained in complete special RPMI-1640 medium with cystine, glutamine, methionine and 10% FBS. Cell growth inhibition was measured by determining total protein with a sulforhodamine B assay as described previously [28] . Briefly, the cells were fixed with 10% trichloroacetic acid, washed with water, stained with sulforhodamine B assay, and washed again. The dye bound to protein was extracted with Tris base and measured at 570 nm with an automated Bio-Kinetics reader (Bio-Tek Instruments, Winooski, Vt., USA). The effect of cystine and methionine depletion and addition on cell growth was determined by comparing the percent growth inhibition with the control group. Experiments were performed in triplicates, and repeated thrice.
Determination of Specific Inhibitor of Cystine Transporter MSG Effect on the Growth of FaDu Cells
FaDu cells (3 ! 10 5 ) were plated in each well of a 12-well plate and allowed to grow overnight with regular RPMI-1640 with 10% FBS. Cells were rinsed with PBS three times and special RPMI-1640 with physiological levels of cystine (84 M ) with 100, 150 and 180 m M MSG alone and in combination with 66 M ␤ -mercaptoethanol (BME) was added. After 24 h of treatment, cells were rinsed with PBS and special RPMI-1640 medium was added and further incubated for 72 h. Photomicrographs were captured with the inverted microscope. Cells were rinsed with PBS, trypsinized, collected and counted with a coulter counter. Percent growth inhibition was compared with the untreated control. The experiment was repeated with duplicate samples.
Effect of Irinotecan on the Growth of FaDu Tumor Xenografts
FaDu tumor xenografts were established using ϳ 50 mg nonnecrotic FaDu tumors pieces in 8-12-week-old female athymic mice (Foxn nu 20-25 g) as described earlier [29] . Mice bearing an established tumor ( ϳ 100-200 mg, 7 days after implantation) were treated with the maximum tolerated dose of irinotecan (100 mg/kg i.v. weekly ! 2). Tumor size was measured on two axes (in millimeters; L, longest axis, and W, shortest axis) with the aid of Vernier calipers as described previously [30] . Tumor weight (mg or mm 3 ) was calculated by using the formula: tumor weight = 1/2 (L ! W 2 ). Twenty-four hours after the first and second dose of irinotecan, tumors were removed from the mice for further analysis.
Western Blot Analysis
FaDu tumor xenografts were collected from nude mice 24 h after the first and second doses of irinotecan (days 8 and 15) and frozen in liquid nitrogen. Tissue homogenates were prepared using a polytron homogenizer in lysis buffer (50 m M Tris-HCl, pH 7.4, 150 m M NaCl, 1% Triton ! 100) containing a protease inhibitor cocktail (Roche, Indianapolis, Ind., USA). Protein extraction was carried out using lysis buffer with FaDu cells treated with 0.1 M SN-38 and untreated cells. Thirty to forty micrograms of protein were electrophoresed and transferred to a PVDF membrane. Western blot was performed with a rabbit polyclonal antibody against xCT (antibody preparation described previously [31] ) and goat polyclonal antibody against xCT (Abcam, Cambridge, Mass., USA) at 1: 500 dilution. Monoclonal p-H2AX antibody (Upstate, Lake Placid, N.Y., USA) was used at 1: 1,000 dilution. All the antibodies were used in 5% milk in phosphate buffered saline with tween 20 (PBS-T) and incubated for 1 h followed by a wash with 5% milk in PBS-T. HRP-conjugated anti-rabbit and anti-mouse antibodies at 1: 5,000 dilution were added in the PBS-T milk for 1 h followed by washing four times with PBS-T (15 min each wash). The ECL-Plus detection kit (GE Biosciences, Piscataway, N.J., USA) was used to detect the protein.
RT-PCR Analysis
Total RNA was isolated from the control and SN-38-treated FaDu cells using the TRIzol reagent (Invitrogen, Carlsbad, Calif., USA) and cDNA was made using the high capacity RNA-tocDNA master mix (Applied Biosystems, Foster City, Calif., USA). PCR was performed using the gene-specific primers, and PCR product was separated on 1% agarose gel to determine the expression levels as described earlier [24] .
Glutathione Assay
FaDu cells were grown in minimum essential medium with 10% FBS containing 84 M cystine, a concentration close to physiological levels [27, 32] , and treated with 0.1 M SN-38 for 24 and 48 h. To determine whether GSH levels were downregulated by SN-38, cells were cultured with and without 66 M BME, a reducing agent that facilitate uptake of cystine by cells via formation of a mixed disulfide consisting of cystine and BME, which is then readily taken up by cells via L-transport system when cystine transporter is inhibited or not functional [33] . FaDu tumor xenografts taken 24 h after the second dose of irinotecan and the respective controls were processed immediately after removal from the mouse for measuring GSH levels. Total GSH was determined using the Glutathione Assay Kit (Calbiochem, San Diego, Calif., USA) according to the manufacturer's protocol. Tumor cells were washed with PBS after treatment, homogenized in cold 5% metaphosphoric acid and centrifuged at 3,000 g for 10 min. Supernatant was collected and used for the assay. Tumor xenografts were washed with 0.9% NaCl solution and blotted on tissue paper. The tissue was weighed minced in cold 5% metaphosphoric acid and homogenized using the polytron homogenizer. The homogenate was centrifuged at 3,000 g , at 4 ° C for 10 min. The clear supernatant was collected and kept at 4 ° C for the assay. A standard curve was prepared with 0, 20, 40, 80 and 100 mol/l GSH in metaphosphoric acid solution and buffer (solution 3) was added to 900 l. 50 l of each reagent, R1 (4-chloro-1-methyl-7-trifluromethylquinolinium methylsulfate) and reagent R2 (30% NaOH) were added, vortexed and incubated at 25 8 3 ° C for 10 min in the dark. The absorbance at 400 nm was determined using a spectrophotometer, and a standard curve was obtained. 100 l of tumor cell extract and tumor xenografts homogenate was added to 900 l of buffer. The reagents R1 and R2 were added and absorbance measured as mentioned above. The concentration of GSH was calculated using the standard curve. The experiment was repeated with three different tumor samples.
Measurement of Intracellular ROS
Intracellular levels of ROS were measured with a 5-(and-6)-carboxy-2 ,7 -dichlorodihydrofluorescein diacetate (Carboxy-H 2 DCFDA) (Molecular Probes, Eugene, Oreg., USA) probe as per the manufacturer's instructions described by us [34] . Briefly, FaDu cells were grown overnight in the 96 well plates and then incubated with CM-DCFDA for 30 min before treating with 0.1 M SN-38. After 2 h of treatment the cells were processed and analyzed by fluorescence (Multi Detection Microplate Reader; BioTek Synergy TM HT, Winooski, Vt., USA) with excitation at 495 nm and emission at 528 nm.
DNA Double-Strand Breaks
DNA double-strand breaks were analyzed in FaDu cells treated with 0.1 M SN-38 and untreated cells by pulsed-field gel electrophoresis (PFGE) as described previously [35] . Briefly, DNA plugs were prepared by using 5 ! 10 6 cells in 2% low melting agarose at 50 ° C and poured into molds to obtain 1 ! 10 6 FaDu cells in each mold. The cells were lysed using lysis buffer (0.5 EDTA, pH 8.0, 10 m M Tris, 1% sarkosyl, and 1 mg/ml of proteinase K) for 24 h at 50 ° C. The DNA plugs were washed with Tris/EDTA buffer treated with RNase A for 1 h and used for electrophoresis on 0.8% agarose gels. Electrophoresis was carried out using Hex-A-Field horizontal gel electrophoresis apparatus at 14 ° C with buffer circulation. Gels were stained with ethidium bromide and photographed on UV-transilluminator.
Immunohistochemical Detection of Phosphorylated Histone H2AX
FaDu tumor xenograft samples were fixed in 10% neutral buffered formalin overnight and were processed for paraffin embedding, and 4-to 5-m sections were mounted on charged slides. Following deparaffinization, sections were incubated in citrate buffer (pH 6) in a microwave for 20 min for antigen retrieval. Endogenous peroxidase was quenched with 3% H 2 O 2 and casein (0.03%) was used to block nonspecific binding. Anti-human antiphospho-H2AX (Ser.139) clone J3W301 mouse Mab (Upstate) in 2 g/ml concentration was applied for 1 h as primary antibody. Elite biotinylated secondary antibody (Vector Labs, Burlingame, Calif., USA) was applied for 30 min followed by incubation with Elite ABC reagent (Vector Labs) for 30 min. The chromogen DAB (Dako, Carpinteria, Calif., USA) was applied for 5 min for visualization of the immunoreactive product. Nuclear counterstaining was done with hematoxylin. Slides were washed between the various steps with PBS/500 l/l Tween. Mouse IgG1, an isotypematched negative control, was used on duplicate slides in place of primary antibody in the same concentration as primary antibody. All immunohistochemical procedures were carried out in automated immunostainer (Dako). The method was developed in our lab, optimized and validated in comparison with pulse field electrophoresis data showing untreated FaDu tumor cells do not have H2AX (known negative control), while SN-38-treated tumor cells show H2AX, a marker of double-strand DNA breaks (known positive control). H2AX expression was assessed semiquantitatively by counting the positive (brown) and negative (unstained) tumor cell nuclei in 6 high-power microscopic fields (400 ! ) and expressed as a percentage of the total nuclei. In order to assess the stained proportion of tumor cell nuclei, the microscopic fields were selected after each other as highly, moderately, less or not labeled areas of the tumor. All studies were reviewed, counted, and interpreted by a board-certified, experienced pathologist (K.T.).
Statistical Analysis
The experimental data presented were obtained from experiments repeated three times with triplicates. Mean values were calculated and significance was determined using the Student's twotailed t test. Tumor xenograft growth curve data were analyzed using GraphPad prism version 5 (La Jolla, Calif., USA) software and p ! 0.05 was considered significant. Tumor growth curves in nude mice were compared using linear regression analysis.
Results
Exogenous Cystine Is Required for Normal Growth of Tumor Cells in vitro
Since some cancer cells and normal cells require the cystine transporter for their growth, the roles of cystine and methionine in support of tumor cells growth were investigated. There was a significant growth inhibition in four tumor cell lines, poorly differentiated human head and neck squamous cell carcinoma (HNSCC) FaDu, well-differentiated HNSCC A253, non-small cell lung carcinoma A549 and prostate cancer cells PC-3 in special RPMI-1640 media (10% FBS) devoid of cystine and methionine ( fig. 1 ). Addition of methionine did not restore growth whereas cystine addition did restore normal growth. This result indicates that cystine is required for the normal growth of cancer cells. The complete growth inhibition of cells was not observed when the cystine and methionine were not present, as reported by others [27] , which could be due to the use of non-dialyzed serum which contains the amino acids. FaDu tumor cells were further used to determine the effect of anticancer agent irinotecan on cystine transporter x c -. To investigate whether the x c -specific inhibitor MSG inhibits the growth of FaDu cells, different concentrations of MSG were used. FaDu cells required high concentration of MSG to inhibit the growth. Recently Olm et al. showed that 60 m M MSG did not affect the cell growth of different human lung carcinoma cells [36] . FaDu cell growth was significantly inhibited by MSG (150-180 m M ) and BME treatment prevented this inhibition effect ( fig. 1 b,  c) . BME alone did not affect the growth.
Treatment with Irinotecan Inhibited Tumor Growth and Reduced the Concentration of GSH
Since irinotecan exerts antitumor activity in vivo in various solid tumor malignancies, we investigated the effect of irinotecan at its maximum tolerated dose (100 mg/ kg) with clinically relevant schedule (twice weekly) on the growth inhibition of FaDu xenografts and GSH concentration. The data presented in figure 2 a demonstrate the significant tumor growth inhibition by irinotecan. The tumor burdens were significantly different in the untreated versus irinotecan-treated groups for time points after 24 h after the first irinotecan treatment. Linear regression analysis of the growth curves showed a significant inhibition (p ^ 0.05) by irinotecan.
To document the association between the observed antitumor activity of irinotecan and its effect on GSH, tumor tissues were removed 24 h after the administration of the 2nd weekly dose of irinotecan and the GSH levels were analyzed. The data in figure 2 b clearly demonstrate that significant reduction of GSH pools were observed at the time of tumor growth inhibition by irinotecan. The GSH levels were decreased by 58% in FaDu xenografts ( fig. 2 b) . To investigate the effect of SN-38 on GSH, FaDu cells were treated with IC 50 (0.1 M ) of SN-38, and intracellular levels of GSH were evaluated; the results are summarized in figure 2 c. In agreement with the in vivo findings, the levels of GSH were inhibited by 31 and 41% at 24 and 48 h of SN-38, respectively. Addition of BME in the medium prevented the reduction of GSH levels by SN-38-treated cells, which is likely due to the BME-induced cystine uptake via formation of mixed disulfide consisting of cysteine and BME. This result suggest that the SN-38 effect is based on interference with the cellular uptake of cystine due to the downregulation of xCT protein, the catalytic light chain of cystine transporter system x c -. Since GSH is involved in the attenuation of ROS generated during oxidative metabolism, the effect of SN-38-induced GSH downregulation on ROS was investigated in FaDu cells. As shown in figure 2 d, SN-38 treatment led to a 40% increase in ROS levels, indicating that there was ROS generation with SN-38 treatment in FaDu cells.
Irinotecan Increased DNA Double-Strand Breaks
The effect of irinotecan on DNA damage was investigated. The results indicate that p-H2AX, a surrogate marker for DNA damage, increased significantly in FaDu xenografts ( fig. 3 a) 24 h after treatment with the therapeutic dose of irinotecan compared to the untreated controls. The percentage of p-H2AX-positive cells in the tumor xenografts was 61% in the irinotecan treatments compared to 2% in untreated controls ( fig. 3 b) . A similar dose-dependent increase of p-H2AX protein was observed by Western blot in FaDu cells treated with SN-38 ( fig. 3 c) . We investigated the DNA double-strand breaks in the FaDu cells treated with SN-38 with pulsed-field gel electrophoresis. As presented in figure 3 d, the DNA double-strand breaks were detected in the FaDu cells treated with SN-38 in vitro.
xCT Was Downregulated by Irinotecan in FaDu Tumor Xenografts and Cells
The availability of cystine is the rate-limiting component for the synthesis of GSH and system x c -is the exchanger for cystine-glutamate, a lack of key component of system x c -(xCT) would be expected to be affected by irinotecan. The effect of irinotecan on xCT expression levels were investigated in FaDu tumor xenografts. As shown in figure 4 a, the effect of irinotecan on xCT protein expression is time dependent and maximum downregulation was found at 24 h after the second weekly treatment. The expression of xCT mRNA and protein were downregulated by SN-38, the active metabolite of irinotecan in FaDu cells ( fig. 4 b, c) . Interestingly, the GSH synthesis regulator ␥ -GCS and its efflux enhancer MRP1 expression levels were not affected by SN-38 ( fig. 4 c) , indicating that GSH downregulation could be due to the downregulation of xCT that compromises the cystine transporter x c -function.
Discussion
The cystine/glutamate exchanger x c -is involved in the transport of cystine, and is a key regulator of cellular GSH levels mediating chemoresistance to cytotoxic agents [16, 37] . Inhibition of the cystine transporter with the aim of depleting GSH has been suggested as a therapeutic potential in treatment of human lymphomas and leukemias [14, 38, 39] , breast cancers [12, 40] and gliomas [41, 42] . High expression of xCT the catalytic partner of system x c -with increased GSH has been correlated to the cisplatin drug resistance in human ovarian cancer cells A2780DDP [43] . There has been considerable interest in xCT as a critical chemotherapeutic target. Sulfasalazine, an inhibitor of xCT, has been suggested for the treatment of prostate cancer [27] . Our results with several human cancer cell lines demonstrate growth inhibition when the cystine was depleted from the medium ( fig. 1 ) . Addition of cystine restored normal growth whereas the methionine, a known precursor of thiols, was not able to restore the normal growth. The cystine/cysteine cycle regulated by x c -has been reported as the key regulatory system for cell survival and cell death and also its over-expression itself protects against oxidative damage by not elevating GSH levels [26] . Cystine uptake mediated by system x c -is required for the growth of normal cells like mouse fibroblast [24] , and is also a rate-limiting step in the synthesis of GSH. A decrease in GSH content has been reported to lead to the generation of oxidative stress and growth arrest of the cells [44] . Irinotecan, an anticancer agent, has been reported to be an inducer of ROS in gastric cancer cells [19] , suggesting its effects on GSH. Irinotecan-mediated anti-tumor activities were extensively evaluated in our laboratory against tumor xenografts [29] . The present study was initiated to determine whether xCT is a target for irinotecan, and whether its inhibition correlated with therapeutic outcome using FaDu tumors as a representation of the cell lines tested. We determined the inhibition of tumor growth by irinotecan ( fig. 2 a) correlated with the downregulation of xCT ( fig. 4 ) . The xCT downregulation resulted in 58% reduction in GSH concentration in xenografts ( fig. 2 b) . These findings indicate that downregulation of xCT could be one of the critical determinants of the in vivo response to irinotecan treatment. Consistent with this, inhibition of the cystine transporter by sulfasalazine in prostate tumors [27] and primary brain tumors [41] has been reported as the primary reason for the growth retardation supporting this contention. Apart from this, Lyons et al. [42] reported that chronic inhibition of xCT leads to smaller glioma tumors that are less invasive compared to controls, suggesting that xCT may play a role in invasion and metastasis besides tumor growth.
The invasive function of xCT appears to be due to the secretion of neurotoxin MSG that leads to cell death and provides extra space in the skull so that glioma cells replicate. This could be a different mechanism by which cells can metastasize. In addition to the observed downregulation of GSH by irinotecan in tumor xenografts, we also found a significant decrease in GSH concentration in the SN-38-treated FaDu cells compared to control cells ( fig. 2 c) . In the presence of BME the GSH levels were restored because the BME induced cystine uptake by forming mixed disulfide consisting of cysteine, and BME prevented the reduction of GSH levels by SN-38-treated cells, which is likely due to the cysteine transportation by an- other transporter, making it available for the GSH synthesis. The decrease in GSH concentration potentially increases the ROS in the cellular system. Consistent with this we found an increase in ROS levels in the SN-38-treated FaDu cells compared to control cells ( fig. 2 d) . SN-38 has been reported as a ROS inducer in gastric cancer cells [19] . Topotecan, a derivative of camptothecin (irinotecan family) exerting the cytotoxic action through the inhibition of topo I, also can cause ROS production [20] . These results are consistent with the data generated with other chemotherapeutic agents such as doxorubicin, daunorubicin, mitoxantrone, bleomycine and cisplatin, which are known to generate ROS that promote oxidative stress [45] [46] [47] [48] [49] [50] [51] .
The increased ROS due to a decrease in GSH could lead to the generation of redox imbalance that may trigger DNA damage. We found an increase in the p-H2AX, a surrogate marker for DNA damage, in the FaDu tumors ( fig. 3 a, b ) treated with irinotecan and in FaDu cells treated with SN-38 ( fig. 3 c) indicating DNA damage. We also demonstrated double-strand breaks ( fig. 3 d) in FaDu cells treated with SN-38. The DNA damage mediated by ROS could be caused by the hydroxylation of guanine [52] and also by the formation of bulky DNA lesions [53] .
We have previously reported that the combination of irinotecan with 5FU is highly synergistic resulting in a 100% cure in mice bearing FaDu xenografts where irinotecan was administered 24 h prior to 5FU [54] . Interestingly, when 5FU was administered 24 h prior to irinotecan with the same dose and schedule, the antitumor efficacy was significantly reduced. The cytotoxic effects of 5FU have been directly linked to the levels of GSH with a 50% decrease resulting in a 20-31% increase in cell kill in HT-29 cells [55] . The decrease of GSH by 5FU has been shown to be due to the inhibition of ␥ -GCS, an enzyme that uses cysteine to synthesize GSH [56] , which is downstream from the xCT inhibition by irinotecan found in this study. Our results presented in figure 4 c also demonstrate that ␥ -GCS expression has not been regulated by SN-38, the active metabolite of irinotecan. Irinotecan targeting xCT could inhibit the cystine transportation inside the cells, resulting in the unavailability of cysteine substrate to ␥ -GCS enzyme to synthesize GSH. The synergistic antitumor efficacy reported by us with the pretreatment with irinotecan followed by 5FU could be due to the upstream inhibition of xCT by irinotecan that reduces the availability of cysteine in the cells. This could be one of the reasons for the synergy of FaDu xenografts when treated with irinotecan prior to 5FU. Thus, drugs such as irinotecan that could modulate intracellular GSH may also regulate the cystine/cysteine cycle. The cystine/ cysteine cycle itself is enough to protect the cells against oxidative damage [26] . Therapeutically targeting this cycle might be more effective in cancer cells when used in combination chemotherapy, due in part to increased intracellular ROS. We have demonstrated the SN-38 inhibitory effects on xCT mRNA ( fig. 4 c) , indicating that SN-38 acts on the transcription of xCT mRNA leading to the downregulation of xCT protein ( fig. 4 b) , which could lead to the inhibition of cystine transporter x c -function. We also found the xCT protein was downregulated in FaDu tumor xenografts ( fig. 4 a) . We did not investigate the effects of irinotecan on the tumor growth promoting stromal cells, including fibroblast and dendritic cells, which secrete cysteine into the tumor microenvironment. Further studies are warranted to find out if irinotecan affects these cells.
In summary, the present investigation identified xCT as a new and potentially critical target of irinotecan in addition to its known target, topo I. Lowering GSH, a known marker for drug resistance, as a consequence of downregulation of xCT could be a critical mechanism associated with the observed therapeutic effect of irinotecan in the model system of FaDu head and neck tumor evaluated in the present study. These findings suggest that xCT could be a target for irinotecan.
